Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
2024年7月30日 - 5:00AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it has
entered into a definitive agreement to acquire privately-held
Tantti Laboratory Inc. (“Tantti”) of Taoyuan City, Taiwan. Tantti
has developed a unique portfolio of macroporous chromatography
beads to optimize the purification of new modalities including
viral vectors, viruses, nucleic acids and other large molecule
biologics.
Tantti’s DuloCore® technology platform combines the
high throughput performance of membranes with the rapid mass
transfer of monoliths in a convenient and flexible bead format.
Combined with AVIPure affinity ligands, the technology will provide
additional performance advantages such as molecule selectivity, and
increased efficiencies to address downstream bottleneck challenges
and scalability concerns of manufacturers. The resins can be
pre-packed for customers into Repligen’s OPUS Columns, where the
company offers the industry’s widest range of sizes for scalability
and efficiency.
Tony J. Hunt, Chief Executive Officer at Repligen
said, “The addition of Tantti further strengthens our portfolio in
the new modality space. Combining Tantti’s innovative bead
technology with the content we are generating from Avitide will be
game-changing. The industry needs high throughput and high-capacity
purification products, and Tantti is the solution to delivering on
this. We are excited to welcome the Tantti team to Repligen, and we
look forward to further developing and integrating their
differentiated technology into our portfolio.”
Joe Yang, Chief Executive Officer at Tantti said,
“We have been working with Repligen for a few years now and we are
thrilled to combine the power of Tantti’s bead technology with the
capabilities of Avitide and to leverage the commercial strength of
Repligen to make DuloCore the gold-standard in the marketplace for
new modality purification. Repligen is the ideal partner for us to
take this next step of growth and we look forward to working with
our colleagues at Repligen to accelerate our market presence in
bioprocessing.”
The acquisition is expected to be completed in the
fourth quarter of this year. The deal is anticipated to be
breakeven on adjusted margins and adjusted earnings per share (EPS)
in 2025 and accretive to adjusted margins and adjusted EPS in
2026.
Approvals and FinancingThe
transaction is expected to be completed by year end 2024, subject
to the satisfaction of customary closing conditions, including
clearance through the Taiwanese regulatory channel. EC Mergers
& Acquisitions is acting as financial advisor and Goodwin
Procter LLP and Tsar & Tsai Law Firm are serving as legal
counsel to Repligen. O’Melveny & Myers LLP and LCS &
Partners are serving as legal counsel to Tantti for the
transaction.
About Tantti Laboratory Inc.Tantti
Laboratory Inc. is a biomaterials engineering company developing
bioprocessing solutions for use in the development and production
of innovative biologic products and advanced cell and gene
therapies. Its key product technology platforms include DuloCore, a
new class of convective chromatography bead resin designed for the
purification of large biomolecules (e.g., viral vectors, nucleic
acids, and viruses). Founded in 2014 and based in Taiwan, Tantti’s
technologies have received patent approval around the world,
including in the United States, Europe, Japan, Taiwan and China.
Visit https://www.tantti.com to learn more.
About Repligen CorporationRepligen
Corporation is a global life sciences company that develops and
commercializes highly innovative bioprocessing technologies and
systems that enable efficiencies in the process of manufacturing
biological drugs. We are “inspiring advances in bioprocessing” for
the customers we serve; primarily biopharmaceutical drug developers
and contract development and manufacturing organizations (CDMOs)
worldwide. Our focus areas are Filtration and Fluid Management,
Chromatography, Process Analytics and Proteins. Our corporate
headquarters are in Waltham, Massachusetts, and the majority of our
manufacturing sites are in the U.S., with additional key sites in
Estonia, France, Germany, Ireland, the Netherlands and Sweden. For
more information about the company see our website at
www.repligen.com, and follow us on LinkedIn.
Forward Looking StatementsThis
press release contains forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned
that statements in this press release which are not strictly
historical statements, including, without limitation, express or
implied statements or guidance regarding the expected results of
the proposed acquisition of Tantti Laboratory Inc. (“Tantti”) on
Repligen’s future financial performance, including the accretive
nature and the timing of the accretive nature of the acquisition,
expected synergies and revenue contribution following the closing
of the Tantti acquisition, customer adoption of Tantti products and
beliefs about the single-use market, the expected expansion of
Repligen’s product lines, and other statements identified by words
like “believe,” “expect,” “anticipate,” “may,” “will,” “should,”
“targeted,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including, without limitation, risks associated with: the risk that
the proposed acquisition may not be completed in a timely manner,
or at all; the occurrence of any event, change or other
circumstance that could give rise to the termination of the
acquisition; Repligen’s ability to integrate Tantti’s business and
personnel and to achieve expected synergies and accretion;
Repligen’s ability to maintain or expand Tantti’s historical sales;
Repligen’s ability to accurately forecast the acquisition, related
costs and allocation of the purchase price, goodwill and other
intangibles acquisition related and other asset adjustments; and
other risks detailed in Repligen’s most recent Annual Report on
Form 10-K subsequently filed Quarterly Reports on Form-10-Q and
Current Reports on Form 8-K on file with the Securities and
Exchange Commission, and the other reports that Repligen
periodically files with the Securities and Exchange Commission.
Actual results may differ materially from those Repligen
contemplated by these forward-looking statements. Therefore, you
should not rely on any of these forward-looking statements. These
forward-looking statements reflect management’s current views and
are based only on information currently available to us. Repligen
does not undertake to update, whether written or oral, any of these
forward-looking statements to reflect a change in its views or
events or circumstances, whether as a result of new information or
otherwise, that occur after the date hereof except as required by
law. The industry and market data contained in this presentation
are based on management’s own estimates, independent publications,
government publications, reports by market research firms or other
published independent sources, and, in each case, are believed by
management to be reasonable estimates. Although we believe these
sources are reliable, we have not independently verified the
information.
Tantti Contact:Steve WangFinancial
Advisor to Tantti +886 9 19456003steve@tantti.com
Repligen Contact:Sondra S.
NewmanGlobal Head of Investor Relations(781)
419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
過去 株価チャート
から 8 2024 まで 9 2024
Repligen (NASDAQ:RGEN)
過去 株価チャート
から 9 2023 まで 9 2024